Skip to content

SABS

SAB Biotherapeutics, Inc.

NASDAQ · Healthcare · Biotechnology · US

$2.60
+2.77%
Ask drillr

Year over year

Reported trailing growth

Revenue
-100.0%
EBITDA
+71.8%
EBIT
-71.7%
EPS
+189.3%
Free cash flow
—
Operating cash flow
—

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
—
EPS
—

Three-year CAGR

Revenue
-100.0%
EBITDA
+157.2%
EBIT
-14.1%
Net income
+138.9%
EPS
+106.0%
Free cash flow
-32.0%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026